Nitric Oxide Nanosensors for Predicting the Development of Osteoarthritis in Rat Model

Jin, Pan; Wiraja, Christian; Zhao, Jinmin; Zhang, Jinlu; Zheng, Li; Xu, Chen

doi:10.1021/acsami.7b06404

Cited by 50 publications

(45 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, developing highly specific theranostic methods is imperative. In recent years, stimulus-responsive smart systems for targeted imaging and precision therapy of OA have attracted increasing interest, such as pH [4,5], ROS [6] or NO [7] triggered drug release systems upon exposure to inflammation tissues in OA. However, triggering by one stimulus usually suffer from 'false positive' or narrow responsive range in the in vivo microenvironments which are dynamically complex and contain various interfering signals.…”

Section: Introductionmentioning

confidence: 99%

MMP-13 Enzyme and pH Responsive Theranostic Nanoplatform for Osteoarthritis

Lan

Chen

Pang

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Stimulus-responsive therapy permits precise control of therapeutic effect only at lesion of interest, which determines it a promising method for diagnosis and imaging-guided precision therapy. The acid environment and overexpressed matrix metalloproteinases-13 (MMP-13) are typical markers in osteoarthritis (OA). However, stimulus-responsive therapeutic platform with high specificity for OA basing on the two markers has not been developed yet. We herein demonstrate a new stimuli-responsive theranostic strategy against OA based on a novel multifunctional nano-micelle which is rationally designed and yet readily synthesized. Such nanoplatform is incorporated with a motif specifically targeting on cartilage, a motif responsive to matrix metalloproteinases-13 to specifically report OA condition and biodynamics of nano-micelles, an anti-inflammatory drug (e.g., psoralidin (PSO)) from traditional Chinese medicine, and a biocompatible polymeric skeleton for sustainable drug release in response to the acidic OA condition. The high effectiveness of this targeted precision therapy is demonstrated comprehensively by both in vitro an in vivo evidences.

show abstract

Section: Introductionmentioning

confidence: 99%

MMP-13 Enzyme and pH Responsive Theranostic Nanoplatform for Osteoarthritis

Lan

Chen

Pang

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Andrographolide could exert protective effects on oxidative stress via activation of the Keap1‐Nrf2‐ARE pathway, and initiate the transcription of ARE genes and the upregulation of antioxidant enzymes (Guan et al, ; Li et al, ; Tan et al, ). Finally, in a rodent experimental model of OA, andrographolide reduced prostaglandin‐endoperoxide synthase 2, MMP13, and NOS2 expression, NO production, and lesions in the joint (Jin et al, ).…”

Section: Discussionmentioning

confidence: 99%

A double‐blind, randomized, placebo‐controlled study to assess the efficacy of Andrographis paniculata standardized extract (ParActin®) on pain reduction in subjects with knee osteoarthritis

Hancke¹,

Srivastav

Cáceres

et al. 2019

Phytotherapy Research

View full text Add to dashboard Cite

Andrographis paniculata Wall (Acanthaceae) is becoming more recognized for its anti‐inflammatory and antioxidant properties. A randomized, double‐blind, placebo‐controlled study was conducted to assess the efficacy of an andrographolide‐containing supplement, ParActin® (300 and 600 mg daily), on Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain reduction in patients with knee osteoarthritis. Joint stiffness, physical function, changes in the SF‐36 quality of life questionnaire, a fatigue scale, and safety were also evaluated. A total of 103 male and female patients with I‐II osteoarthritis of the knee joint were assessed. Patients treated with 300 or 600 mg/day of ParActin® showed a significant reduction in pain at days 28, 56, and 84 compared with a placebo group. WOMAC stiffness scores, physical function score, and the fatigue score showed a significant improvement in both ParActin®‐treated groups compared with the placebo group. At the end of the study, the quality of life (SF‐36 questionnaire) and Functional Assessment of Chronic Illness Therapy (FACIT) scores showed significant improvements in both ParActin®‐treated groups compared with the placebo group. Overall, it can be concluded that ParActin® in 300 and 600 mg/day dosages were found to be effective and safe in reducing pain in individuals suffering from mild to moderate knee osteoarthritis.

show abstract

“…Signi cant efforts have focused on engineering drug delivery systems to prolong the retention time of drug in the joint [5,6]. In recent years, emerging stimulusresponsive smart systems for targeted imaging and precision therapy have attracted increasing interest, such as pH [7,8], ROS [9] or NO [10] triggered drug release systems upon exposure to in ammation tissues, which not only prolonged drug release, but also increased speci city to tissue and cells. The selection of optimal stimulus for the smart drug delivery system is the key for OA therapy.…”

Section: Introductionmentioning

confidence: 99%

MMP-13 Enzyme and pH Responsive Theranostic Nanoplatform for Osteoarthritis

Lan

Chen

Pang

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Stimulus-responsive therapy permits precise control of therapeutic effect only at lesion of interest, which determines it a promising method for diagnosis and imaging-guided precision therapy. The acid environment and overexpressed matrix metalloproteinases-13 (MMP-13) are typical markers in osteoarthritis (OA), which enables the development of stimulus-responsive drug delivery system with high specificity for OA. We herein demonstrate a nano-micelle based stimuli-responsive theranostic strategy with reporting and drug release controlled by acidic PH and MMP-13 for OA therapy. Such nanoplatform is incorporated with a motif specifically targeting on cartilage, a motif responsive to matrix metalloproteinases-13 to specifically report OA condition and biodynamics of nano-micelles, an anti-inflammatory drug (e.g., psoralidin (PSO)) from traditional Chinese medicine, and a biocompatible polymeric skeleton for sustainable drug release in response to the acidic OA condition. The high effectiveness of this targeted precision therapy is demonstrated comprehensively by both in vitro and vivo evidences.

show abstract

Nitric Oxide Nanosensors for Predicting the Development of Osteoarthritis in Rat Model

Cited by 50 publications

References 28 publications

MMP-13 Enzyme and pH Responsive Theranostic Nanoplatform for Osteoarthritis

MMP-13 Enzyme and pH Responsive Theranostic Nanoplatform for Osteoarthritis

A double‐blind, randomized, placebo‐controlled study to assess the efficacy of Andrographis paniculata standardized extract (ParActin®) on pain reduction in subjects with knee osteoarthritis

MMP-13 Enzyme and pH Responsive Theranostic Nanoplatform for Osteoarthritis

Contact Info

Product

Resources

About